Skip to content

News

Report from 2017 AACR Special Conference Addressing Critica...

Report from 2017 AACR Special Conference Addressing Critical Questions in Ovarian Cancer Research and Treatment

(October 13, 2017) Every other year, the American Association for Cancer Research (AACR) brings together ovarian cancer researchers from around the world to share knowledge and encourage multi-disciplinary collaboration. At this year’s conference, held October 1-4 in Pittsburgh, Pennsylvania, a focus on critical questions led to energetic discussions about ways to take information from basic … Continued

Research

OCRFA’s Response to Trump Administration’s Birth Cont...

OCRFA’s Response to Trump Administration’s Birth Control Coverage Rollback

(Oct. 11, 2017) Last week, the Trump Administration issued a regulation to immediately allow employers to deny insurance coverage for birth control on the basis of their own moral or religious objections, undermining the landmark benefit under the Affordable Care Act (ACA) that guarantees coverage for contraception without co-pays or cost-sharing. Audra Moran, President and … Continued

Advocacy

Studies Show that Current Chemotherapy Dosage is Still Best...

Studies Show that Current Chemotherapy Dosage is Still Best Option for Epithelial Ovarian Cancer

(September 15, 2017) Two studies just confirmed that, depending on one’s genetic background, the standard treatment for epithelial ovarian cancer is most likely the best option. The studies, conducted with two different populations, showed that, although the outcomes conflicted one another, the option that offered the best progression free survival was the one already used. … Continued

Research

Folonari Wines Partners with OCRFA

Folonari Wines Partners with OCRFA

(September 8, 2017) Through its ongoing ‘AMORE, ITALIA, FOLONARI’ campaign, Folonari Wines has partnered this year with Ovarian Cancer Research Alliance. Joining forces with OCRFA gives Folonari a national platform to continue their fight against ovarian cancer with the ‘Time to Teal with Folonari’ campaign. Frederick Wildman and Sons will working together with its trade … Continued

Community

The Link Between Chemotherapy Resistance and a Tumor’s BRCA...

The Link Between Chemotherapy Resistance and a Tumor’s BRCA1/2 Mutations

(September 5, 2017) Researchers at the University of Pennsylvania recently uncovered a link between one’s resistance to common types of chemotherapy and one’s tumor BRCA1/2 mutation status. More specifically, they looked at both copies of the BRCA genes, one copy given by each parent. Until recently, it had been assumed that mutated BRCA gene left … Continued

Research

Share Your #OvarianStory to Raise Awareness

Share Your #OvarianStory to Raise Awareness

Every 23 minutes another woman is diagnosed with ovarian cancer. All of them have a story. This September, we’re inviting you to share your #OvarianStory. Help raise awareness of ovarian cancer, from the first often-missed symptoms, to diagnosis and beyond. By speaking out, you can help other women and you can shine a spotlight on … Continued

Community

Newk’s Eatery “Joins the Fight” Against O...

Newk’s Eatery “Joins the Fight” Against Ovarian Cancer with Fundraiser

(August 31, 2017) In answer to the persisting need for a cure to one of the deadliest diseases facing women today, Newk’s Eatery is calling on partners and patrons across its 115 restaurants to “Join the Fight” against ovarian cancer. During Ovarian Cancer Awareness Month this September, guests both dining in or ordering online are … Continued

Community

Genetic Testing Rates Found to be Low in Women With A Histo...

Genetic Testing Rates Found to be Low in Women With A History of Breast or Ovarian Cancer

(August 22, 2017) The Journal of Clinical Oncology recently published a study about the unmet need of genetic testing in women with breast and ovarian cancer. Women who fit eligibility criteria from the National Comprehensive Cancer Network (NCCN) took surveys focusing on discussions about genetic testing with a health professional, being advised to have genetic … Continued

Research

FDA Approves New Indication and Formulation for Olaparib

FDA Approves New Indication and Formulation for Olaparib

(August 21, 2017) The US Food and Drug Administration (FDA) has granted full approval to olaparib tablets (Lynparza, AstraZeneca) for use as maintenance therapy for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to platinum-based chemotherapy. This is not only a new indication for … Continued

Research

Age When Giving Birth and Oral Contraceptives Influence One...

Age When Giving Birth and Oral Contraceptives Influence One’s Risk of Ovarian Cancer

(August 9, 2017) The International Journal of Cancer recently published an article on preliminary findings for two factors that influence one’s risk of ovarian cancer, namely the age at which a woman gives birth and the age at which she starts using oral contraceptives. The authors, including Celeste Leigh Pearce, PhD of OCRFA’s Scientific Advisory … Continued

Research

Updated Patient Resources for Ovarian Cancer from the Natio...

Updated Patient Resources for Ovarian Cancer from the National Comprehensive Cancer Network

(July 31, 2017) The National Comprehensive Cancer Network (NCCN), has updated and published guidelines for patients with ovarian cancer. There are two parts to the resource guide: The Guidelines for Patients and Quick Guides. The NCCN Guidelines for Patients is an in depth look at topics such as testing, stages of cancer, and treatments. There … Continued

Research

OCRFA Funded Project Has Breakthrough on Therapeutic Approa...

OCRFA Funded Project Has Breakthrough on Therapeutic Approach for Rare Ovarian Cancer

(July 27, 2017) Earlier this week, in Nature Cell Biology, researchers at The Wistar Institute published their findings about a few strategies to treat clear cell carcinoma. Clear cell is a rare form of ovarian cancer that does not usually respond well to platinum-based chemotherapy, which leaves patients with few options. In most cases of … Continued

OCRA News

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.